crizanlizumab
crizanlizumab is listed in the FDA National Drug Code directory with 1 NDC code, marketed under brand name including ADAKVEO. Available dosage form: injection.
Drug Details
- Generic Name
- crizanlizumab
- Brand Names
- ADAKVEO
- Application Number
- BLA761128
- Sponsor
- Novartis Pharmaceuticals Corporation
- NDC Codes
- 1
- Dosage Forms
- INJECTION
- Routes
- INTRAVENOUS
- Active Ingredients
- CRIZANLIZUMAB
Indications and Usage
1 INDICATIONS AND USAGE ADAKVEO ® is indicated to reduce the frequency of vaso-occlusive crises (VOCs) in adults and pediatric patients aged 16 years and older with sickle cell disease. ADAKVEO is a selectin blocker indicated to reduce the frequency of vasoocclusive crises in adults and pediatric patients aged 16 years and older with sickle cell disease.